Search results for "Angiotensin"

showing 10 items of 396 documents

Telmisartan as metabolic modulator: a new perspective in sports doping?

2011

The World Antidoping Agency (WADA) has introduced some changes in the 2012 prohibited list. Among the leading innovations to the rules are that both 5-aminoimidazole-4-carboxamide-1-[beta]-D-ribofuranoside (peroxisome proliferator�activated receptor-[delta] [PPAR-[delta]]-5' adenosine monophosphate-activated protein kinase [AMPK] agonist) and GW1516 (PPAR-[delta]-agonist) are no longer categorized as gene doping substances in the new 2012 prohibited list but as metabolic modulators in the class �Hormone and metabolic modulators.� This may also be valid for the angotensin II receptor blocker telmisartan. It has recently been shown that telmisartan might induce similar biochemical, biological…

Agonistmedicine.medical_specialtymedicine.drug_classPeroxisome proliferator-activated receptorPhysical Therapy Sports Therapy and RehabilitationdopingBenzoatesMiceGene dopingInternal medicinemedicineAnimalsHumansOrthopedics and Sports MedicineTelmisartanMuscle SkeletalDoping in Sportschemistry.chemical_classificationFiber typeTelmisartan; doping; sport.business.industryAMPKGeneral MedicineRatssport.EndocrinologyMitochondrial biogenesischemistryBenzimidazolesTelmisartanbusinessAngiotensin II Type 1 Receptor Blockersmedicine.drug
researchProduct

Aldosterone synthase activity in the Y-1 adrenal cell line.

1995

The Y-1 adrenal cell line was shown to produce 20 alpha-dihydroaldosterone from deoxycorticosterone. This compound was identified by GC-MS by comparison with the previously synthesized reference compound. Two other 18-hydroxylated metabolites were identified as 11 beta,18-dihydroxy-20 alpha-dihydroprogesterone from endogenous cholesterol and 18-hydroxy-20 alpha-dihydro-11-dehydrocorticosterone from DOC. The conditions necessary for the synthesis of these compounds are culturing in 20% serum-supplemented medium and repeated incubations with the substrate. The production of 11 beta-hydroxylated steroids and that of 18-oxygenated steroids is stimulated differently by ACTH and angiotensin II su…

Aldosterone synthasemedicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and MetabolismClinical BiochemistryBiochemistryGas Chromatography-Mass SpectrometryCell LineMiceEndocrinologyAdrenocorticotropic HormoneCytochrome P-450 Enzyme SystemInternal medicineMineralocorticoidsmedicineAnimalsCytochrome P-450 CYP11B2RNA MessengerDesoxycorticosteroneMolecular BiologyGlucocorticoidschemistry.chemical_classificationbiologyAdrenal cortexAngiotensin IICytochrome P450Cell BiologyAngiotensin IIEnzymeEndocrinologymedicine.anatomical_structurechemistryBiochemistryCell cultureMineralocorticoidbiology.proteinAdrenal CortexMolecular MedicineSteroid 11-beta-HydroxylaseGlucocorticoidmedicine.drugThe Journal of steroid biochemistry and molecular biology
researchProduct

AT1 receptors mediate contractile effects of Angiotensin II on mouse colon

2011

Angiotensin II (Ang II) is a potent smooth muscle contractile neurohumoral agonist via interaction with AT1 and AT2 receptors. Although these receptors are well expressed in the gut, very little research has been devoted to analysed the physiological role played by Ang II (and its receptors) in the regulation of gastrointestinal motility. The effects of Ang II on mouse proximal and distal colon contractility, the receptor subtypes involved were investigated in vitro, using the organ bath technique. Longitudinally-oriented segments from mouse proximal and distal colon displayed ongoing contractile activity, characterized by phasic contractions. Ang II induced a concentration-dependent muscul…

Angiotensin II
researchProduct

Angiotensin II positively modulates the spontaneous contractile activity of mouse and human colon via activation of AT1 receptors.

2012

Objective: Angiotensin II (Ang II) is a potent smooth muscle contractile neurohumoral agonist but has not been much investigated with regard to gastrointestinal motor activity. Ang II effects are mediated by specific receptors, the Ang II type 1 (AT1) and the Ang II type 2 (AT2) receptors, which are well expressed in the gut. In this study we evaluated the effects of Ang II on the contractile activity of longitudinal muscle from mouse and human colon and we analysed the subtype(s) of receptors involved in the observed effects. Methods: Mechanical responses to Ang II, in the absence or in the presence of different drugs, were assessed in vitro in colonic longitudinal muscle from mice and hum…

Angiotensin II gastrointestinal tract AT1 receptors mouse human colon.
researchProduct

ANALISI DEI MECCANISMI DI CONTROLLO DELLA MOTILITA’ GASTROINTESTINALE DA PARTE DI ORMONI COINVOLTI NEL BILANCIO IDRICO-SALINO

2014

Angiotensin II vasopressinhormonehumanenteric nervous system (ENS)mouse
researchProduct

Focus on clinical practice: angiotensin-converting enzyme 2 and corona virus disease 2019: pathophysiology and clinical implications.

2020

: ACE2 receptor has a broad expression pattern in the cellular membrane and provides a protective action against the development of cardiovascular diseases. Recently, this enzyme has become of extreme interest during the pandemic infection of COVID-19 (coronavirus disease 2019). This virus invades alveolar epithelium and cardiomyocytes using ACE2 as a transmembrane receptor. ACE2 is a counter-regulatory peptide that degrades Ang II into Ang 1-7, thereby attenuating the biological effects of the AT1 receptor. The binding between the spike protein of COVID-19 and the enzyme is crucial for the virus to enter the target cells, but whether an increase in ACE2 activity could facilitate the infect…

Angiotensin receptorARDSMyocarditisPneumonia ViralAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologyPharmacologyPeptidyl-Dipeptidase AVirusSettore MED/11Renin-Angiotensin System03 medical and health sciencesAngiotensin Receptor AntagonistsBetacoronavirus0302 clinical medicinemedicineHumans030212 general & internal medicineReceptorPandemicsDisseminated intravascular coagulationAngiotensin II receptor type 1business.industrySARS-CoV-2COVID-19General MedicineVirus Internalizationmedicine.diseaseCardiovascular DiseasesAngiotensin-converting enzyme 2Spike Glycoprotein CoronavirusAngiotensin-Converting Enzyme 2Cardiology and Cardiovascular MedicinebusinessCoronavirus Infectionshormones hormone substitutes and hormone antagonistsJournal of cardiovascular medicine (Hagerstown, Md.)
researchProduct

Effects of ACE-Inhibitors and Angiotensin Receptor Blockers on Inflammation

2011

The role of inflammation in cardiovascular disease and in hypertensive disease above all, is complex. Several studies confirm that activation of renin-angiotensin-aldosterone system (RAAS), through increase in the production of angiotensin II (Ang II), is closely related to local vascular inflammation. Over the BP lowering effects of anti-hypertensive treatments, several ancillary effects for every class may be found, distinguishing the various drugs from one another. Given the pro-inflammatory effects of Ang II and aldosterone, agents that interfere with the components of RAAS, such as ACE inhibitors, Angiotensin Receptor Blockers (ARBs), and mineralocorticoid receptor antagonists (spirono…

Angiotensin receptorSettore MED/09 - Medicina InternaAngiotensin-Converting Enzyme InhibitorsBlood PressureInflammationPharmacologyRenin-Angiotensin SystemAngiotensin Receptor Antagonistschemistry.chemical_compoundMineralocorticoid receptorDrug DiscoveryAnimalsHumansMedicineInflammationPharmacologyAngiotensin II receptor type 1Aldosteronebusiness.industryAngiotensin IIEplerenoneexercise cytokines inflammationchemistryCardiovascular DiseasesHypertensionSpironolactonemedicine.symptombusinessmedicine.drugCurrent Pharmaceutical Design
researchProduct

Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure

2015

Background— Clinical trials in heart failure have focused on the improvement in symptoms or decreases in the risk of death and other cardiovascular events. Little is known about the effect of drugs on the risk of clinical deterioration in surviving patients. Methods and Results— We compared the angiotensin-neprilysin inhibitor LCZ696 (400 mg daily) with the angiotensin-converting enzyme inhibitor enalapril (20 mg daily) in 8399 patients with heart failure and reduced ejection fraction in a double-blind trial. The analyses focused on prespecified measures of nonfatal clinical deterioration. In comparison with the enalapril group, fewer LCZ696-treated patients required intensification of med…

Angiotensin receptorVascular damage Radboud Institute for Health Sciences [Radboudumc 16]receptorsTetrazolesheart failureAngiotensin-Converting Enzyme InhibitorsKaplan-Meier EstimateSacubitrilAngiotensin; Heart failure; Neprilysin; Receptors; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Double-Blind Method; Enalapril; Heart Failure; Humans; Kaplan-Meier Estimate; Natriuretic Peptide Brain; Neprilysin; Peptide Fragments; Risk Factors; Stroke Volume; Survivors; Tetrazoles; Treatment Outcome; Troponin; Disease Progression; Medicine (all); Cardiology and Cardiovascular Medicine; Physiology (medical)AngiotensinEnalaprilRisk FactorsEnalapril/therapeutic useNatriuretic Peptide BrainHeart Failure/bloodSurvivorsReceptorNeprilysinAminobutyrates: Systèmes cardiovasculaire & respiratoire [D03] [Sciences de la santé humaine]Troponin/bloodTroponinAngiotensin Receptor Antagonists/therapeutic useDrug CombinationsAngiotensin-Converting Enzyme Inhibitors/therapeutic useTreatment OutcomeTetrazoles/therapeutic useCardiologyDisease ProgressionValsartanNeprilysinHeart Failure/blood/drug therapy/physiopathologyCardiology and Cardiovascular Medicinemedicine.drugReceptormedicine.medical_specialtyHeart failureneprilysinAngiotensin Receptor Antagonistsreceptors angiotensinDouble-Blind MethodPhysiology (medical)Internal medicineRenin–angiotensin systemmedicineHumansheart failure neprilysin receptors angiotensinEnalaprilbusiness.industryBiphenyl CompoundsStroke Volumemedicine.diseasePeptide FragmentsEndocrinologyAminobutyrates/therapeutic useStroke Volume/physiologyHeart failureNatriuretic Peptide Brain/blood: Cardiovascular & respiratory systems [D03] [Human health sciences]businessNeprilysin/antagonists & inhibitorsPeptide Fragments/bloodSacubitril ValsartanBiomarkersBiomarkers/blood
researchProduct

Hypovolaemia-induced metabolic dysfunction, mediated in part by aldosterone and angiotensin

2009

Angiotensin receptormedicine.medical_specialtyAldosteroneAngiotensin II receptor type 1Physiologybusiness.industrychemistry.chemical_compoundEndocrinologychemistryHypovolemiaInternal medicineRenin–angiotensin systemInternal Medicinemedicinemedicine.symptomCardiology and Cardiovascular MedicinebusinessJournal of Hypertension
researchProduct

The angiotensin (1-7)/MAS receptor axis and vascular cell inflammation

2014

Angiotensin receptormedicine.medical_specialtyAngiotensin II receptor type 1Angiotensin 1ChemistryCellMas receptorInflammationEndocrinologymedicine.anatomical_structureInternal medicinemedicinemedicine.symptomCardiology and Cardiovascular MedicineAtherosclerosis
researchProduct